×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
NYSEAMERICAN:MTNB

Matinas BioPharma Stock Forecast, Price & News

$0.83
+0.04 (+5.06%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.79
$0.85
50-Day Range
N/A
52-Week Range
$0.49
$1.61
Volume
727,622 shs
Average Volume
380,622 shs
Market Capitalization
$180.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Matinas BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
261.4% Upside
$3.00 Price Target
Short Interest
Healthy
1.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.13) to ($0.12) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.40 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Matinas BioPharma logo

About Matinas BioPharma (NYSEAMERICAN:MTNB) Stock

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

MTNB Stock News Headlines

Matinas Biopharma GAAP EPS of -$0.03
Matinas Biopharma Q1 2022 Earnings Preview
Here's Why Matinas BioPharma Shares Are Rising
Matinas BioPharma: Q4 Earnings Insights
Matinas Biopharma GAAP EPS of -$0.03 beats by $0.01
Matinas Biopharma Q4 2021 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:MTNB
CIK
N/A
Fax
N/A
Employees
31
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/06/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+261.4%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-23,280,000.00
Pretax Margin
-69,849.70%

Debt

Sales & Book Value

Annual Sales
$30,000.00
Book Value
$0.24 per share

Miscellaneous

Free Float
199,299,000
Market Cap
$180.00 million
Optionable
Not Optionable
Beta
1.98














Matinas BioPharma Frequently Asked Questions

Should I buy or sell Matinas BioPharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Matinas BioPharma stock.
View analyst ratings for Matinas BioPharma
or view top-rated stocks.

What is Matinas BioPharma's stock price forecast for 2022?

2 Wall Street research analysts have issued 1 year price targets for Matinas BioPharma's shares. Their MTNB stock forecasts range from $3.00 to $3.00. On average, they anticipate Matinas BioPharma's share price to reach $3.00 in the next year. This suggests a possible upside of 261.4% from the stock's current price.
View analysts' price targets for Matinas BioPharma
or view top-rated stocks among Wall Street analysts.

How has Matinas BioPharma's stock performed in 2022?

Matinas BioPharma's stock was trading at $0.9462 at the start of the year. Since then, MTNB stock has decreased by 12.3% and is now trading at $0.83.
View the best growth stocks for 2022 here
.

When is Matinas BioPharma's next earnings date?

Matinas BioPharma is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Matinas BioPharma
.

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its quarterly earnings results on Thursday, May, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03).
View Matinas BioPharma's earnings history
.

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the following people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 48, Pay $795k)
  • Dr. Theresa Matkovits Ph.D., Chief Devel. Officer (Age 55, Pay $525.52k)
  • Dr. James J. Ferguson FACC, M.D., Chief Medical Officer (Age 67, Pay $586.3k)
  • Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 52)
  • Dr. Hui Liu M.B.A., Ph.D., Chief Technology Officer (Age 54)
  • Dr. Raphael J. Mannino Ph.D., Chief Scientific Officer (Age 75)
  • Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain
  • Mr. Thomas J. Hoover M.B.A., Chief Bus. Officer (Age 52)

What other stocks do shareholders of Matinas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), OrganiGram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS).

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.83.

How much money does Matinas BioPharma make?

Matinas BioPharma (NYSEAMERICAN:MTNB) has a market capitalization of $180.00 million and generates $30,000.00 in revenue each year. The company earns $-23,280,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

How many employees does Matinas BioPharma have?

Matinas BioPharma employs 31 workers across the globe.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The official website for Matinas BioPharma is www.matinasbiopharma.com. The company can be reached via phone at (908) 443-1860 or via email at mtnb@jtcir.com.

This page (NYSEAMERICAN:MTNB) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.